NHS Approves First Ovarian Cancer Drug in 20 Years

Hundreds of women with advanced ovarian cancer now have access to a breakthrough treatment that's been approved for NHS use after 20 years without new options.

The National Institute for Health and Care Excellence has approved mirvetuximab soravtansine for women whose late-stage ovarian, fallopian tube, or peritoneal cancers have stopped responding to chemotherapy. For these patients, treatment choices were previously extremely limited.

The new therapy works like a biological missile, attaching directly to cancer cells and destroying them from within. Clinical trials show it extends survival by an average of four months compared to chemotherapy alone, and NHS England expects 400 women each year to benefit.

But the real breakthrough might be in quality of life. The drug is given by drip once every three weeks, with dramatically milder side effects than traditional chemotherapy.

Patricia Hill, a 64-year-old retired NHS physiotherapist from north London, knows this firsthand. After three rounds of conventional chemotherapy left her bedridden, she started the new treatment in January.

"This is the first time that I've actually been able to get on with my life in terms of the impact of side effects," Hill said. "The feelings of isolation and loneliness that you have undergoing conventional chemotherapy are totally or more or less totally eradicated."

She describes it simply: "It actually adds life to years, rather than spending your life in bed recovering from the side effects of chemotherapy."

The Ripple Effect

The approval matters beyond individual patients. Many ovarian cancers are diagnosed at advanced stages when treatment becomes exponentially harder, and being told that platinum-based chemotherapy has stopped working brings enormous anxiety and uncertainty.

Victoria Clare, CEO of the charity Ovacome, called it "a landmark moment" that offers the ovarian cancer community "an additional choice at a critical stage, with the potential to make a real difference to patients and their families."

Professor Ruth Plummer, NHS England's national clinical lead for cancer drugs, noted this represents "the most significant breakthrough in NHS treatment for these hard-to-treat ovarian cancers in over two decades."

After years of waiting, hundreds of women now have hope for precious extra time with the people they love.